We found that CLL development was similar in TCL1 and TCL1-AIDKO mice, with CD5/CD19 double-positive CLL cells appearing in peripheral blood of both cohorts, leading to a median overall survival of approximately one year (Figure 2A). The gene discussed is CD5; the disease is B-cell chronic lymphocytic leukemia.